Symbiomix Therapeutics Names David L. Stern to CEO Post

Xconomy New York — 

Symbiomix Therapeutics has hired David L. Stern to become the CEO of the Newark, NJ-based drug developer. Stern previously served as chief commercial officer of New York biotech Celmatix. His experience also includes various management roles at OvaScience (NASDAQ: OVAS) and Merck Serono.